-
Bosutinib may stop the disease progression for some ALS patients
A 12-week phase I dose-escalation trial open label has been launched in early 2021 in Japan to evaluate the safety and tolerability of Bosutinib.
The results of this clinical trial had just been announced.
Of the nine patients who drank 100-300 milligrams of bosutinib daily for 12 weeks, five stopped progressing, the remaining four remained progressing at the same pace.
-
0 Replies
Sorry, there were no replies found.
Log in to reply.